Author: Gábor Winkler1,2
View More View Less
  • 1 Szent János Kórház, Budapest, Diós árok 1–3., 1125
  • | 2 Miskolci Egyetem, Egészségügyi Kar, Miskolc
Open access

Absztrakt

A metformin a 2-es típusú diabetes vércukorcsökkentő kezelésének alapgyógyszere: a hatályos kezelési irányelvek szerint ellenjavallat/intolerancia hiányában adását a betegség egész tartamában fenn kell tartani, inzulinkezelés bevezetését követően is. Az utóbbi időben mind több részlet vált ismertté hatásai molekuláris hátterét illetően, a megismeréssel párhuzamosan nőtt azonban a megválaszolásra váró újabb kérdések száma is. Az áttekintő közlemény a szer klinikai farmakológiájával és hatásspektrumával kapcsolatos már kikristályosodott, illetve újabb adatokat járja körül. Röviden kitér a hatását potenciálisan befolyásoló genetikai polimorfizmusokra és gyógyszer-interakciókra is. Orv. Hetil., 2016, 157(23), 882–891.

  • 1

    Rojas, L. B., Gomes, M. B.: Metformin: an old but still the best treatment for type 2 diabetes. Diabetol. Metab. Syndr., 2013, 5(1), 6. http://www.dmsjournal.com/content/5/1/6

  • 2

    Viollet, B., Guigas, B., Sanz Garcia, N., et al.: Cellular and molecular mechanisms of metformin: an overview. Clin. Sci., 2012, 122(6), 253–270.

  • 3

    Gaál, Zs., Gerő, L., Hidvégi, T., et al.: Diagnosis, treatment and care of diabetes mellitus in adults. Guideline of the Hungarian Diabetes Association, 2014. [A diabetes mellitus kórismézése, a cukorbetegek kezelése és gondozása a felnőttkorban. A Magyar Diabetes Társaság szakmai irányelve, 2014.] Diabetol. Hung., 2014, 22(Suppl. 1), 2–84. [Hungarian]

  • 4

    Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al.: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38(1), 140–149.

  • 5

    Garber, A. J., Abrahamson, M. J., Bazilay, J. I., et al.: Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorythm – 2016 executive summary. Endocr. Pract., 2016, 22(1), 84–113.

  • 6

    Gong, L., Goswami, S., Giacomini, K. M., et al.: Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics, 2012, 22(11), 820–827.

  • 7

    Naderpoor, N., Shorakae, S., de Courten, B., et al.: Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum. Reprod. Update, 2015, 21(5), 560–574. Corrigendum, 2016, 22(1), 1–2.

  • 8

    Sussman, J. B., Kent, D. M., Nelson, J. P., et al.: Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ, 2015, 350, h454.

  • 9

    Oner, G., Ozcelik, B., Ozgun, M. T., et al.: The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Hum. Reprod., 2010, 25(4), 932–937.

  • 10

    Foda, A. A., Aal, I. A.: Metformin as a new therapy for endometriosis, its effects on both clinical picture and cytokines profile. Middle East Fertil. Society J., 2012, 17(4), 262–267.

  • 11

    Koh, S. J., Kim, J. M., Kim, I. K., et al.: Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. J. Gastroenterol. Hepatol., 2014, 29(3), 502–510.

  • 12

    Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., et al.: Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife, 2014, 3, e02242.

  • 13

    Nakano, M., Inui, A.: Metformin and incretin-based therapies up-regulate central and peripheral adenosine monophosphate-activated protein affecting appetite and metabolism. Indian J. Endocrinol. Metab., 2012, 16(Suppl. 3), S529–S531.

  • 14

    Buse, J. B., DeFronzo, R. A., Rosenstock, J., et al.: The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care, 2016, 39(2), 198–205.

  • 15

    Song, R.: Mechanism of metformin: a tale of two sites. Diabetes Care, 2016, 39(2), 187–189.

  • 16

    Graham, G. G., Punt, J., Arora, M., et al.: Clinial pharmacokinetics of metformin. Clin. Pharmacokinet., 2011, 50(2), 81–98.

  • 17

    Pandit, V., Pai, R. S., Yadav, V., et al.: Pharmacokinetic and pharmacodynamic evaluation of floating microspheres of metformin hydrochloride. Drug Dev. Ind. Pharm., 2013, 39(1), 117–127.

  • 18

    FDA: Metformin hydrochloride. http://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf

  • 19

    Timmins, P., Donahue, S., Meeker, J., et al.: Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin. Pharmacokinet., 2005, 44(7), 721–729.

  • 20

    Shah, A. D., McHargue, C., Yee, J., et al.: Intravenous contrast in patients with diabetes on metformin: new common sense guidelines. Endocr. Pract., 2016, 22(4), 502–505.

  • 21

    Andreucci, M., Solomon, R., Tasanarong, A.: Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. BioMed Res. Int., 2014, 2014, Article ID 741018.

  • 22

    Eyal, S., Easterling, T. R., Carr, D., et al.: Pharmacokinetics of metformin during pregnancy. Drug Metab. Dispos., 2010, 38(5), 833–840.

  • 23

    Rowan, J. A., Rush, E. C., Obolonkin, V., et al.: Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU): body composition at 2 years of age. Diabetes Care, 2011, 34(10), 2279–2284.

  • 24

    Feig, D. S., Moses, R. G.: Metformin therapy during pregnancy. Good for the goose and good for the gosling too? Diabetes Care, 2011, 34(10), 2329–2330.

  • 25

    Rena, G., Pearson, E. R., Sakamoto, K.: Molecular mechanism of action of metformin: old or new insights? Diabetologia, 2013, 56(9), 1898–1906.

  • 26

    Shackelford, D. B., Shaw, R. J.: The LKB1–AMPK pathway: metabolism and growth control in tumor suppression. Nat. Rev. Cancer, 2009, 9(8), 563–575.

  • 27

    Natali, A., Ferrannini, E.: Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia, 2006, 49(3), 434–441.

  • 28

    Rosso, P., Fioramonti, M., Fracassi, A., et al.: AMPK in the central nervous system: physiological roles and pathological implications. Res. Rep. Biol., 2016, 7, 1–13.

  • 29

    Mulherin, A. J., Oh, A. H., Kim, H., et al.: Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology, 2011, 152(12), 4610–4619.

  • 30

    Tajima, K., Shirakawa, J., Togashi, Y., et al.: AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration. PloS ONE, 2013, 8(5), e64633.

  • 31

    Cubeddu, L. X., Bönisch, H., Göthert, M., et al.: Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 361(1), 85–91.

  • 32

    Hoffmann, I. S., Roa, M., Torrico, F., et al.: Ondansetron and metformin-induced gastrointestinal side effects. Am. J. Ther., 2003, 10(6), 447–451.

  • 33

    Batchuluun, B., Sonoda, N., Takayanagi, R., et al.: The cardiovascular effects of metformin: conventional and new insights. J. Endocrinol. Diabetes Obes., 2014, 2(2), 1035.

  • 34

    Forslund, K., Hildebrand, F., Nielsen, T., et al.: Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature, 2015, 528(7581), 262–266.

  • 35

    Bai, A., Ma, A. G., Yong, M., et al.: AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem. Pharmacol., 2010, 80(11), 1708–1717.

  • 36

    Amini, F. G., Rafieian-Kopaei, M., Nematbakhsh, M., et al.: Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J. Res. Med. Sci., 2012, 17(7), 621–625.

  • 37

    Nasri, R. H.: Renoprotective effects of metformin. DARU J. Pharmaceutical Sci., 2013, 21(1), 36.

  • 38

    Roussel, R., Travert, F., Pasquet, B., et al.: Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med., 2010, 170(21), 1892–1899.

  • 39

    Eurich, D. T., Weir, D. L., Majumdar, S. R., et al.: Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ. Heart Fail., 2013, 6(3), 395–402.

  • 40

    Inzucchi, S. E., Lipska, K. J., Mayo, H., et al.: Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA, 2014, 312(24), 2668–2675.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 0 7 19
Feb 2021 0 12 19
Mar 2021 0 5 7
Apr 2021 0 4 3
May 2021 0 4 5
Jun 2021 0 5 2
Jul 2021 0 0 0